investorscraft@gmail.com

Stock Analysis & ValuationKlotho Neurosciences, Inc. (KLTO)

Previous Close
$0.00
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

13576 Walnut Street
Omaha, NE 68144
United States
Phone: 833 931 6330
Industry: Biotechnology
Sector: Healthcare
CEO: Joseph Sinkule
Full Time Employees: 3

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.

HomeMenuAccount